2026. Sustained On- and Off-Treatment Disease Control in Patients With Moderate-to-Severe Atopic Dermatitis Following 12-Week, Open-Label, Once-Daily Abrocitinib 200 mg: A Post Hoc Analysis of the Phase 3 JADE REGIMEN Study. SKIN The Journal of Cutaneous Medicine. 10, 2 (Mar. 2026), s732. DOI:https://doi.org/10.25251/v9pqj003.